- Molecular NameCandesartan
- SynonymCandesartan cilexetil
- Weight440.463
- Drugbank_IDDB00796
- ACS_NO139481-59-7
- Show 3D model
- LogP (experiment)5.282
- LogP (predicted, AB/LogP v2.0)3.24
- pka5.3
- LogD (pH=7, predicted)-1.66
- Solubility (experiment)Insoluble
- LogS (predicted, ACD/Labs)(ph=7)-2.59
- LogSw (predicted, AB/LogsW2.0)0.03
- Sw (mg/ml) (predicted, ACD/Labs)0.0
- No.of HBond Donors2
- No.of HBond Acceptors9
- No.of Rotatable Bonds7
- TPSA118.81
- StatusFDA approved
- AdministrationN/A
- PharmacologyAn angiotensin II receptor antagonist used mainly for the treatment of hypertension.
- Absorption_valueN/A
- Absorption (description)Candesartan cilexetil is absorbed after oral administration with an absolute bioavailability for candesartan of about 40% following administration of a solution or 14% following administration of tablets.
- Caco_2N/A
- Bioavailability42.0
- Protein binding99.8
- Volume of distribution (VD)0.14 L/kg
- Blood/Plasma Partitioning ratio (D_blood)N/A
- MetabollsmCandesartan cilexetil: intestinal wall; candesartan: hepatic (CYP2C9). Candesartan is the active metabolite.
- Half life9.7 h
- ExcretionRenal 33%, faecal 67%. It is excreted in urine and bile mainly as unchanged drug and a small amount of inactive metabolites.
- Urinary Excretion52
- Clerance0.37 ml/min/kg
- ToxicityThe most common reasons for discontinuation of therapy with Candesartan were headache (0.6%) and dizziness (0.3%). The adverse events that occurred in placebo-controlled clinical trials in at least 1% of patients treated with Candesartan and at a higher incidence in candesartan (n = 2350) than placebo (n = 1027) patients included back pain (3% vs. 2%), dizziness (4% vs. 3%), upper respiratory tract infection (6% vs. 4%), pharyngitis (2% vs. 1%), and rhinitis (2% vs. 1%).
- LD50 (rat)N/A
- LD50 (mouse)N/A